Lixte Biotechnology Holdings, Inc. (8640.MU)
| Previous close | 2.2200 |
| Open | 2.2200 |
| Bid | 2.0400 x N/A |
| Ask | 2.3200 x N/A |
| Day's range | 2.2200 - 2.2200 |
| 52-week range | 1.7300 - 6.5400 |
| Volume | |
| Avg. volume | 78 |
| Market cap | 4.993M |
| Beta (5Y monthly) | -0.23 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
LIXTE Biotechnology Holdings Provides Update on Recent Activities
Publishing of Findings in Recent Pre-Clinical Study for LIXTE’s Proprietary Compound, LB-100, in New Field of Cancer Biology, “Activation Lethality”Presentation at MedInvest Biotech and Pharma Investor ConferenceCo-Sponsorship/Presentation of Workshop at Harvard University’s Dana Farber Cancer Institute PASADENA, CA, May 20, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new cla
- GlobeNewswire
LIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer”
Recent Findings Relate to LIXTE’s Lead Clinical Compound, LB-100, to be Presented at Workshop on May 9 and 10 at Harvard’s Dana Farber Cancer Institute in Boston PASADENA, CA, May 08, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced it is co-sponsoring an international scientific workshop on “Therapeutic Over-Activation in Cancer” at Harvard University’s Dana Farber Cancer Ins
- GlobeNewswire
NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIES
LB-100 IS SYNERGISTIC WITH WEE1 INHIBITION IN KILLING CANCER CELLS; FINDING OPENS NEW TREATMENT STRATEGY IN ADDITION TO THREE CURRENT LIXTE CLINICAL TRIALS PASADENA, CA, March 27, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, announced today publication of pre-clinical data in the online journal, Cancer Discovery, showing that its lead clinical compound, LB-100, can force cancer cells to g
